"10.1371_journal.pone.0060339","plos one","2013-04-05T00:00:00Z","Adel Tabchy; Nevine Eltonsy; David E Housman; Gordon B Mills","Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America; Kleberg Center for Molecular Markers, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America; Sheikh Zayed Bin Sultan Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America; The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America","Critical revision of manuscript and final approval: AT NE DEH GBM. Conceived and designed the experiments: AT NE DEH GBM. Performed the experiments: AT NE. Analyzed the data: AT NE DEH GBM. Contributed reagents/materials/analysis tools: AT NE. Wrote the paper: AT GBM.","GBM received sponsored research from GSK to determine molecular markers predicting response to PI3K pathway inhibitors. GBM has support from Exelixis, Celgene, Wyeth and Astra Zeneca to determine response to drugs not involved in this study. GBM is on the oncology Advisory Board of Astra Zeneca. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials. The other authors declare no competing interests.","2013","04","Adel Tabchy","AT",4,FALSE,4,2,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
